Novartis AG (NYSE:NVS) is on Jim Cramer’s radar, with shares up 44% in the past year and 7.6% year-to-date. Analysts like Morgan Stanley upgraded the shares to Overweight with a price target of CHF110. TD Cowen reiterated a Hold rating with a $140 target, expressing concerns about growth projections. Cramer is optimistic about Novartis’ cancer drug Pluvicto.

While Novartis (NVS) shows promise, some AI stocks may offer higher returns with less downside risk. For those interested in an inexpensive AI stock benefiting from Trump tariffs, check out a free report on the best short-term AI stock. For more stock recommendations, explore 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Original article published on Insider Monkey.

Read more at Yahoo Finance: Jim Cramer is Optimistic About Novartis’ (NVS) Cancer Drug